Braveheart Bio reported third quarter 2026 financial results, ending the period with $503.5 million in cash and investments, providing a runway into 2029. The company highlighted 52-week clinical data for BHB-1893 in obstructive HCM and outlined an updated Phase 3 development strategy designed to simplify dosing and minimize titration.
Term
Q3 2026
“BHB-1893 continues to show a consistent, potentially differentiated profile across multiple clinical studies and our mechanistic work. The 52-week data presented at AHA showed rapid, deep responses that continued to improve over time, including meaningful improvements in pVO2 and KCCQ-CSS, and evidence supporting a highly simplified dosing regimen.”
Travis Murdoch, M.D., President and Chief Executive Officer
Grove Collaborative reported its third quarter 2026 financial results, achieving its first quarter of positive net income since becoming a public company. While total net revenue declined 15.8% year-over-year to $36.8 million, it grew 0.7% sequentially, marking the second consecutive quarter of sequential growth. The company also narrowed its full-year 2026 revenue guidance to a range of $144 million to $146 million.
Term
Q3 2026
“Third quarter results reflect the operating discipline we have built over the past several quarters. Net Revenue grew sequentially for the second consecutive quarter to $36.8 million. We also delivered positive Adjusted EBITDA for the fourth consecutive quarter, and delivered positive Adjusted EBITDA and net income in the same quarter for the first time since becoming a publicly-traded company.”
Jeff Yurcisin, Chief Executive Officer of Grove Collaborative
Orchestra BioMed reported a significant decrease in total revenue to $0.29 million for the nine months ended September 30, 2026, compared to $2.57 million in the prior year, primarily due to the absence of partnership revenue. The company's total stockholders' equity declined from $53.6 million to $7.8 million as the accumulated deficit reached $425.8 million.
Opus Genetics reported a significant increase in net loss to $120.1 million for the nine months ended September 30, 2026, primarily driven by a $72.8 million fair value change in financial instruments. Despite the loss, the company strengthened its balance sheet through $82.9 million in financing activities, including a note purchase agreement and Series B preferred stock issuance, ending the period with $89.0 million in cash and cash equivalents.
For the nine months ended September 30, 2026, ParkerVision reported a net loss of $0.5 million and a working capital deficit of $0.8 million. The company expressed substantial doubt about its ability to continue as a going concern, noting that its liquidity is dependent on successful patent licensing, litigation settlements, and potential additional financing.
TELA Bio reported Q3 2026 revenue of $19.0 million, an 8% decrease year-over-year primarily due to lower OviTex PRS volumes. The company implemented a strategic cost reduction initiative to reduce annual operating expenses by $17.0 million and extend its cash runway into 2028. During the quarter, the company also regained Nasdaq compliance and received 510(k) clearance for its Liora Monofilament Scaffold.
Term
Q3 2026
“My first quarter as CEO was focused on putting a plan in place to return TELA Bio to growth. I joined because I believe OviTex is best-in-class technology and that we are well positioned to win in an evolving soft tissue repair and reconstruction market.”
Heather Getz, Chief Executive Officer of TELA Bio
“Our cost reduction initiative allows us to thoughtfully reallocate resources, supports a return to topline growth, and extends our cash runway. In the third quarter alone, we reduced our adjusted EBITDA loss by 55% versus the second quarter of 2026 while delivering sequential revenue growth in the US hernia market and continued year-over-year growth in Europe.”
Grayscale Ethereum Classic Trust reported a net asset value of $94.9 million as of September 30, 2026, a decrease from $126.0 million at year-end 2025. The Trust experienced a net loss from operations of $31.1 million for the nine months ended September 30, 2026, primarily driven by $29.5 million in unrealized depreciation of its Ethereum Classic holdings.
Achieve Life Sciences (rebranded as AchieveRx) reported third quarter 2026 financial results and provided a regulatory update on its smoking cessation drug, cytisinicline. The company remains on track to resubmit its New Drug Application (NDA) to the FDA in Q4 2026 and ended the period with $201.5 million in cash and equivalents.
Term
Q3 2026
“Becoming AchieveRx, The Quit Company, reflects our shift from a clinical-stage company to one preparing to launch what could be the first new FDA-approved prescription medicine in 20 years to help people who smoke quit.”
Andrew D. Goldberg, MD, Chief Executive Officer
“Our 52-week ORCA-OL results add to the growing body of evidence supporting cytisinicline as a potential treatment option for people looking to quit smoking. With an experienced launch team and our NDA resubmission on track for later this year, we are well positioned to bring cytisinicline to people who want to quit, if it is approved.”
Ambow Education reported Q3 2026 financial results with net revenues increasing 21.4% year-over-year to $1.7 million, driven by growth in both educational programs and HybriU licensing. The company reduced its net cash used in operating activities by half during the first nine months of the year while increasing investments in R&D and marketing ahead of CES 2027.
Public Policy Holding Company reported revenue of $55.2 million for the third quarter of 2026, up from $48.8 million in the prior year period. Despite a loss from operations of $8.3 million, the company achieved a small net income of $0.2 million for the quarter, aided by a $9.8 million gain on a bargain purchase. Total assets grew to $259.8 million as of September 30, 2026, compared to $202.6 million at year-end 2025.
Grocery Outlet reported Q3 2026 financial results with net sales increasing 0.9% to $1.18 billion and a return to positive comparable store sales growth of 0.5%. Net income rose to $13.3 million, or $0.13 per diluted share, despite a 40 basis point decline in gross margin driven by product promotions and higher transportation costs.
Term
Q3 2026
“In the third quarter we returned to positive comparable store sales, driven by continued improvements to the execution of our opportunistic product offering. Traffic accelerated and basket trends again improved sequentially as we enhanced our value proposition.”
ParkerVision reported a net loss of $0.5 million for the first nine months of 2026, a significant improvement from the $7.4 million loss in the prior year period. The results were driven by a 46% reduction in operating expenses and a $3.4 million gain from the fair value adjustment of contingent payment obligations. Management also provided updates on ongoing patent litigation against Qualcomm, MediaTek, and Realtek, as well as a FOIA complaint against the National Archives.
Term
9 months ended September 30, 2026
“While we believe bifurcation of our Qualcomm case is inefficient, the appellate court's decision does not impact the merits of our case, and we are eager to pursue a jury trial on our transmitter claims as expeditiously as possible.”
Jeffrey Parker, CEO of ParkerVision
“We are looking forward to a response from the National Archives given that, to date, nearly a year since responsive documents have been identified, we have still not received any of the identified responsive documents to our request.”
Bionano Genomics reported Q3 2026 revenue of $8.3 million, a 12% increase year-over-year, driven by a 24% rise in consumables revenue. The company reiterated its full-year 2026 revenue guidance of $31 million to $33 million and highlighted progress in the clinical adoption of its optical genome mapping (OGM) technology.
Term
Q3 2026
“Our third quarter results reflect the momentum building across our business and the broader genomics community, further accelerating the adoption of optical genome mapping (OGM) in clinical and commercial settings.”
Al Luderer, Ph.D., chairman and interim chief executive officer
“Coverage and regulatory progress this quarter helped build a clearer reimbursement pathway for OGM-based testing, which we expect to support broader clinical adoption over time.”
Al Luderer, Ph.D., chairman and interim chief executive officer
Worksport Ltd. reported record Q3 2026 net sales of $7.2 million, a 44.2% increase year-over-year, driven by strong performance of its NEXUS product line. The company's net loss narrowed by 27% to $3.6 million as revenue growth significantly outpaced the increase in operating expenses. Management highlighted a 95% reduction in operating cash use since Q1 2026 as the company moves toward a just-in-time production model.
For the three months ended September 30, 2026, Grayscale Bitcoin Cash Trust reported a net increase in net assets resulting from operations of $39.3 million, driven by $40.2 million in unrealized appreciation of BCH. The Trust's net assets grew from $76.6 million at the start of the period to $115.9 million, while the Principal Market NAV per Share increased from $1.62 to $2.46.
Sally Beauty Holdings reported fiscal 2026 consolidated net sales of $3,734.6 million, a 0.9% increase driven by favorable foreign currency and a 0.5% increase in comparable sales. While consolidated net earnings grew 2.1% to $200.1 million, operating earnings saw a slight 0.4% decrease due to the absence of a prior-year gain on a headquarters sale.
SilverBox Corp V reported a net income of $6,127,724 for the nine months ended September 30, 2026, primarily driven by $7,405,656 in interest earned on investments held in the Trust Account. The company remains a shell company with $284,174,540 in Class A ordinary shares subject to possible redemption and a total shareholders' deficit of $20,552,951.
Mercury Systems reported record first quarter fiscal 2027 results with revenue of $253 million, up 12.4% year-over-year, and record bookings of $370 million. The company achieved GAAP net income of $13 million and record adjusted EBITDA of $56 million, leading management to raise its full-year fiscal 2027 outlook. Additionally, the company formalized CFO David E. Farnsworth's role as Chief Operating Officer.
Term
Q1 2027
“We delivered strong first quarter fiscal 2027 results, with record first quarter bookings, revenue, and adjusted EBITDA, and record backlog. Our first quarter results reflect robust organic growth and margins that are in-line with our target profile. Based on this solid execution, we are raising our outlook for fiscal year 2027.”
Smart Sand, Inc. reported total revenue of $112.3 million for the third quarter of 2026, a significant increase from $92.8 million in the same period of 2025. Net income for the nine months ended September 30, 2026, rose to $14.7 million compared to $0.2 million in the prior year, driven primarily by higher sand sales volumes and improved gross margins.
SunHydrogen, Inc. reported a net loss of $2,463,097 for the three months ended September 30, 2026, compared to a loss of $1,559,778 in the prior year period. The company remains in the development stage with no revenue from product sales, while total assets decreased slightly to $31.2 million as of September 30, 2026.
Smart Sand reported Q3 2026 revenue of $112.3 million and net income of $8.4 million, driven by strong sales volumes in core operating basins. The company generated $17.3 million in free cash flow during the quarter and expects full-year 2026 sales volumes to increase by 20% to 30% compared to 2025.
Term
Q3 2026
“Smart Sand delivered another outstanding quarter of operational and financial results. In the quarter, we achieved strong sales volumes, contribution margin, Adjusted EBITDA and generated over $17.0 million in free cash flow.”
Charles Young, Smart Sand’s Chief Executive Officer
“We continue to see robust activity in our core operating basins, and we currently expect these activity levels to continue through the fourth quarter and into 2027.”
Charles Young, Smart Sand’s Chief Executive Officer
Sonoma Pharmaceuticals reported a significant revenue increase to $13.58 million for the six months ended September 30, 2026, compared to $9.62 million in the prior year. The company successfully narrowed its net loss to $396,000 from $1.78 million, driven by improved gross profits and a return to positive income from operations in the most recent quarter.
Usio, Inc. reported third quarter 2026 financial results with revenue increasing 12% to $23.7M and Adjusted EBITDA rising 222% to $1.2M. The company achieved its third consecutive quarter of positive GAAP net income, driven by record ACH transaction volumes and expansion in its PayFac business.
Term
Q3 2026
“It was another strong quarter for Usio, with revenue increasing 12% and Adjusted EBITDA rising 222%, driven by sustained transaction growth and improving operating leverage. Total payment dollars processed increased 25% to $2.73 billion, while total payment transactions grew 27% to 20.7 million. ACH transactions increased 39%, setting a new quarterly record for the sixth consecutive quarter.”
Louis Hoch, President and Chief Executive Officer of Usio
“Looking ahead, we are particularly encouraged by the opportunities presented by Usio Ion and our recently announced strategic partnership with Harris Computer. Ion has the potential to deepen our existing customer relationships, expand our third-party owned deposit base and generate incremental high-margin interest revenue, while our preferred payments provider relationship with Harris expands our reach into the utility market.”
Louis Hoch, President and Chief Executive Officer of Usio
Inovio Pharmaceuticals reported a net loss of $49.2 million for the third quarter of 2026, with total assets decreasing to $60.1 million from $74.3 million at year-end 2025. The company highlighted substantial doubt about its ability to continue as a going concern, noting that current working capital is only sufficient to fund operations through the fourth quarter of 2027.
For the nine months ended September 30, 2026, the Grayscale Avalanche Staking ETF reported a net decrease in net assets from operations of $364,000, despite generating $95,000 in staking reward income. The Trust's net assets grew to $7.9 million as of September 30, 2026, driven by capital share transactions and a recovery in unrealized appreciation during the third quarter.
Sky Harbour Group Corp reported total revenue of $10.58 million for the third quarter of 2026, a 45% increase year-over-year, driven by growth in both rental and fuel revenue. Despite the revenue growth, the company recorded an operating loss of $6.27 million and a net loss of $2.82 million for the quarter, though this was an improvement from the $4.65 million net loss in the prior year period.
Worksport Ltd reported net sales of $15.77 million for the nine months ended September 30, 2026, a significant increase from $11.36 million in the prior year period. Despite the revenue growth, the company recorded a net loss of $13.39 million for the period, driven by high general, administrative, and marketing expenses.
American Vanguard reported Q3 2026 net sales of $108 million and a net loss of $17.7 million, citing difficult global agricultural market conditions driven by El Niño and geopolitical instability. Despite international headwinds, the company highlighted U.S. outperformance and the acquisition of four U.S. brands from Syngenta to drive future growth. Management revised its full-year 2026 outlook, now expecting sales of $500-$530 million and Adjusted EBITDA of $36-$40 million.
“Our actions are taking hold, and the progress we are making across American Vanguard continues to build, even as market conditions remain difficult, particularly outside the U.S., where El Niño is materially impacting our business this year.”
Dak Kaye, CEO of American Vanguard
“We began to see progress this quarter in terms of lower operating costs and improved manufacturing efficiencies as a result of actions taken earlier this year. However, this progress was more than offset in the quarter by the effects of negative operating leverage, driven by lower international sales.”
For the nine months ended September 30, 2026, Apollo Realty Income Solutions reported total revenues of $60.1 million and net income of $49.6 million, compared to $24.8 million and $50.5 million respectively in the prior year period. The company significantly expanded its real estate portfolio, with total assets increasing to $2.68 billion from $2.08 billion at year-end 2025.
Usio, Inc. reported a significant turnaround for the nine months ended September 30, 2026, with net income of $0.6 million compared to a net loss of $1.0 million in the prior year period. Total revenues grew 15.4% to $72.9 million, driven by increased gross profit and improved operating leverage as SG&A expenses remained relatively flat.